Translating our pioneering research to treatments for patients requires cooperative partnerships across many different organizations ranging from universities, hospitals, research centers, biobanks as well as industry partners such as pharmaceutical and biotechnology companies. Without industry partnership, new medicines, treatments and diagnostics for patients stemming from Genuity Science’s research, would not be possible.
Bringing commercial expertise of pharmaceutical and biotechnology companies to Genuity Science’s research will maximize patient benefit of Genuity Science’s research. Working closely with us, our industry partners will have restricted read only access to select de-identified datasets (which contain only the information they need for their specific and approved research study) in order to turn research findings into treatments and diagnostics. Before commencing commercially-partnered research, Genuity Science enters into legal agreements with all partners, which strictly controls their activities. These researchers are prohibited from attempting to identify an individual participant from the data in the database. Read more information on our data stewardship practices.
Genuity Science (then Genomics Medicine Ireland and WuXi NextCODE) commenced a partnership with AbbVie in 2017. As part of the collaboration, Genuity Science is conducting population genomics research aimed at advancing the discovery of novel therapeutic approaches to major chronic diseases.
Read our announcement about our AbbVie partnership.
Genuity Science began a multi-year partnership with Ionis Pharmaceuticals in 2020. The collaboration leverages Genuity Science’s unique approach of combining high-quality, whole-genome sequence and deep phenotype data resulting in better definition of the underlying disease mechanisms. This approach, when coupled with Ionis’ proprietary antisense technology, has the potential to significantly expedite the drug development process through a more direct translation of targets into therapeutics.
Read our announcement about our Ionis partnership.
Genuity Science began a multi-year agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The aim is to understand patient variability among lupus and lupus nephritis patients to better understand disease severity and symptoms and facilitate the targeting of more refined patient subpopulations that may enable the advancement of therapeutic agents.
Genuity Science began a multi-year agreement in 2021 with GSK. The goal of the engagement is to bring together a comprehensive database to enable the evaluation of variability among patients with heart failure and among patients with liver disease in order to better understand disease severity and symptoms. It is designed to facilitate the identification of more refined patient subpopulations that may eventually enable the advancement of specific therapeutic agents in specific patient subpopulations.
Genuity Science began a multi-year agreement with Neuron23 in 2022. The goal of the engagement is to bring together a comprehensive database to enable the evaluation of variability among patients with Multiple Sclerosis in order to better understand the disease. It is designed to facilitate the identification of more refined patient subpopulations that may eventually enable the advancement of specific therapeutic agents in specific patient subpopulations.
Genuity Science began a multi-year agreement in 2022 with Vesalius Therapeutics. The goal of the collaboration is to bring together a comprehensive database to enable the evaluation of variability among patients with Parkinson’s disease to better understand disease severity and symptoms. It is designed to facilitate the identification of more refined patient subpopulations that may eventually enable the advancement of specific therapeutic agents in specific patient subpopulations.
Genuity Science began a 1-year agreement in 2023 with Tenaya Therapeutics. The goal of the collaboration is to enable the evaluation of variability among patients with Heart Failure in order to better understand disease severity and symptoms. It is designed to facilitate the identification of more refined patient subpopulations that may eventually enable the advancement of specific therapeutic agents in specific patient subpopulations.
Hospital, Academic and Clinical Research Centers (Ireland)
Emory University (US)
Nashville Biosciences (US)
Primary Care Centers (UK)
University of Cambridge (UK)
University of Massachusetts Medical Center (US)
University of Southern California (US)
Vanderbilt University Medical Center
Yale University Medical Center (US)
